Cosentex: First-Line Systemic


Welcome to the Cosentyx website

Cosentyx is the only fully human anti-IL-17A to be approved in Europe for the first-line systemic treatment of patients with moderate-to-severe plaque psoriasis, and is also indicated for patients with psoriatic arthritis and ankylosing spondylitis 1

Find out how Cosentyx can help your patients with psoriasis achieve lasting clear or almost clear skin with monthly subcutaneous self-injections1


~ 8/10 patients achieve PASI 90 at week 162

Find out more


90% of PASI 90 response at week 16 seen at week 521

Find out more


Well tolerated in over 6,800 patients1

Find out more


  1. Cosentyx Summary of Product Characteristics, May 2016.
  2. Thaçi D et al. J Am Acad Dermatol 2015; 73(3): 400-409.
  3. European Medicines Agency. Guideline On Clinical Investigation Of Medicinal Products Indicated For The Treatment Of Psoriasis, November 2004.
  4. Girolomoni G, et al. Br J Dermatol 2012; 167(4): 717-24.

NP4 code: GLDEIM/AIN457A/0356

Terms of use Privacy policy About cookies

© 2016 Novartis Pharma